Sanofi’s Phase III multiple myeloma trial meets primary goal

Sanofi has reported that the Phase III IMROZ clinical trial of its monoclonal antibody Sarclisa (isatuximab) plus standard-of-care for multiple myeloma (MM) met the primary endpoint.